medigraphic.com
Colegio de Medicina Interna de México.

2023, Número 6

<< Anterior Siguiente >>

Med Int Mex 2023; 39 (6)


Albúmina humana: indicaciones basadas en la evidencia

Garnica CCE

Idioma: Español
Referencias bibliográficas: 47
Paginas: 908-919
Archivo PDF: 237.17 Kb.


RESUMEN

La albúmina es la proteína circulante más abundante del cuerpo y a lo largo del tiempo se ha intentado descifrar su importancia clínica. Desde 1940 se ha usado en distintos escenarios clínicos. Sus propiedades protectoras de la microvasculatura y del glicocálix son las que se consideran al momento de tratar pacientes con daño endotelial (hipovolemia, sepsis, quemaduras); no obstante, no hay indicaciones detalladas para su administración. En esta reseña se desglosarán las indicaciones aceptadas y se sugerirán protocolos para un uso de manera concienzuda.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Italian Association for the Study of the Liver (AISF); ItalianSociety of Transfusion Medicine and Immunohaematology(SIMTI). AISF-SIMTI Position Paper: The appropriate use ofalbumin in patients with liver cirrhosis. Dig Liver Dis 2016;48 (1): 4-15. Doi: 10.1016/j.dld.2015.11.008.

  2. Fanali G, di Masi A, Trezza V, Marino M, et al. Human serumalbumin: from bench to bedside. Mol Aspects Med 2012;

  3. 33: 209-90. Doi: 10.1016/j.mam.2011.12.002.3. Peters T. All about albumin: biochemistry, genetics, andmedical applications. United States: Academic Press, 1995.https://doi.org/10.1016/B978-0-12-552110-9.X5000-4.

  4. Skillman JJ, Restall DS, Salzman EW. Randomized trial ofalbumin vs. electrolyte solutions during abdominal aorticoperations. Surgery 1975; 78 (3): 291-303.

  5. Cochrane Injuries Group Albumin Reviewers. Human albuminadministration in critically ill patients: systematic reviewof randomised controlled trials. BMJ 1998; 317 (7153):235-240. https://doi.org/10.1136/bmj.317.7153.235.

  6. Wilkes MM, Navickis RJ. Patient survival after humanalbumin administration. A meta-analysis of randomized,controlled trials. Ann Intern Med 2001; 135 (3):149-64. Doi:10.7326/0003-4819-135-3-200108070-00007.

  7. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, NortonR; SAFE Study Investigators. A comparison of albumin andsaline for fluid resuscitation in the intensive care unit.N Engl J Med 2004; 350 (22): 2247-56. Doi: 10.1056/NEJMoa040232.

  8. Caironi P, Tognoni G, Masson S, Fumagalli R, et al. Albuminreplacement in patients with severe sepsis or septic shock.N Engl J Med 2014; 370 (15): 1412-1421. doi:10.1056/NEJMoa1305727.

  9. Annane D, Siami S, Jaber S, Martin C, et al. Effects of fluidresuscitation with colloids vs crystalloids on mortality incritically ill patients presenting with hypovolemic shock:The CRISTAL randomized trial. JAMA 2013; 310 (17): 1809-1817. Doi: 10.1001/jama.2013.280502.

  10. Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trialsof human albumin for adults with sepsis: systematic reviewand meta-analysis with trial sequential analysis of all-causemortality [published correction appears in BMJ. 2014; 349:g4850]. BMJ 2014; 349: g4561. doi:10.1136/bmj.g4561.

  11. Consejo de Salubridad General (2017). Cuadro Básico y Catálogode Medicamentos. http://www.csg.gob.mx/descargas/pdf/priorizacion/cuadro-basico/med/catalogo/2017/EDICION_2017_MEDICAMENTOS-FINAL.pdf.

  12. US Food & Drug Administration. (2018). Albumin (Human)(None). https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/albumin-human-none.

  13. Bernardi M, Angeli P, Claria J, Moreau R, et al. Albuminin decompensated cirrhosis: new concepts and perspectives.Gut 2020; 69 (6): 1127-1138. Doi: 10.1136/gutjnl-2019-318843.

  14. Bosques-Padilla FJ, Rivera-Ramos JF, Rizo-Robles MT,Medina-González A, Torres-Flores E. Guías clínicas dediagnóstico y tratamiento de la ascitis. Aspectos terapéuticosde la ascitis no complicada. Rev Gastroenterol Mex2009; 74 (4).

  15. Castro-Narro G, Moctezuma-Velázquez C, Male-VelázquezR, Trejo-Estrada R, et al. Position statement on the useof albumin in liver cirrhosis. Ann Hepatol 2022; 27 (4):100708. doi:10.1016/j.aohep.2022.100708.

  16. Wong F, Pappas C, Curry MP, Reddy R, et al. Terlipressinplus albumin for the treatment of type 1 hepatorenalsyndrome. N Engl J Med 2021; 384:818-828. Doi: 10.1056/NEJMoa2008290.

  17. Carvalho JR, Verdelho Machado M. New insights aboutalbumin and liver disease. Ann Hepatol 2018; 17 (4): 547-560. Doi: 10.5604/01.3001.0012.0916.

  18. Yu YT, Liu J, Hu B, Wang RL, et al. Expert consensus on theuse of human serum albumin in critically ill patients. ChinMed J (Engl) 2021; 134 (14): 1639-1654. doi:10.1097/CM9.0000000000001661.

  19. Evans L, Rhodes A, Alhazzani W, Antonelli M, et al. Survivingsepsis campaign: international guidelines for managementof sepsis and septic shock 2021. Intensive Care Med 2021;47 (11): 1181-1247. doi:10.1007/s00134-021-06506-y.

  20. Zhou S, Zeng Z, Wei H, Sha T, An S. Early combination of albuminwith crystalloids administration might be beneficialfor the survival of septic patients: a retrospective analysisfrom MIMIC-IV database. Ann Intensive Care 2021; 11 (1):42. doi:10.1186/s13613-021-00830-8.

  21. Sakr Y, Gattinoni L; SepNet-Critical-Care-Trials-Gruppe.Randomisierte kontrollierte multizentrische Studie zur Albuminersatztherapieim septischen Schock (ARISS) [Randomizedcontrolled multicenter study of albumin replacementtherapy in septic shock (ARISS)]. Anaesthesist 2021; 70(6): 528-530. German. Doi: 10.1007/s00101-021-00952-5.

  22. Jeschke MG, van Baar ME, Choudhry MA, Chung KK, GibranNS, Logsetty S. Burn injury. Nat Rev Dis Primers 2020; 6 (1):11. doi:10.1038/s41572-020-0145-5.

  23. Causbie JM, Sattler LA, Basel AP, Britton GW, Cancio LC.State of the art: An update on adult burn resuscitation.Eur Burn J 2021; 2 (3): 152-167. https://doi.org/10.3390/ebj2030012.

  24. Navickis RJ, Greenhalgh DG, Wilkes MM. Albumin in burnshock resuscitation: A meta-analysis of controlled clinicalstudies. J Burn Care Res 2016; 37 (3): e268-e278. Doi:10.1097/BCR.0000000000000201.

  25. Haberal M, Abali S, Karakayali H. Fluid management inmajor burns injuries. Indian J Plast Surg 2010; 43. Doi:10.4103/0970-0358.70715.

  26. Chung KK, Wolf SE, Cancio LC, Alvarado R, et al. Resuscitationof severely burned military casualties: fluid begetsmore fluid. J Trauma 2009; 67 (2): 231-237. doi:10.1097/TA.0b013e3181ac68cf.

  27. Satahoo SS, Palmieri TL. Fluid resuscitation in burns: 2 cc,3 cc, or 4 cc? Curr Trauma 2019; Rep 5: 99-105 (2019).https://doi.org/10.1007/s40719-019-00166-6.

  28. Vincent JL, Russell JA, Jacob M, Martin G, et al. Albuminadministration in the acutely ill: what is new and wherenext? Critical Care 2014; 18: 231. doi: 10.1186/cc13991.

  29. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemiain acute illness: is there a rationale for intervention?A meta-analysis of cohort studies and controlledtrials. Ann Surg 2003; 237 (3): 319-34. doi: 10.1097/01.SLA.0000055547.93484.87.

  30. Myburgh JA, Finfer S. Albumin is a blood product too—isit safe for all patients? Crit Care Resusc 2009; 11: 67-70.

  31. Rozga J, Piatek T, Malkowski P. Human albumin: old, new,and emerging applications. Ann Transplant 2013; 18: 205-217. doi: 10.12659/AOT.889188.

  32. Al-Khafaji, et al. Albumin in the critically ill. TransfusionAlternatives Transfusion Med 2003; 5: 4.

  33. Busuioc RM, Mircescu G. Nephrotic syndrome complications- new and old. Part 1. Maedica (Bucur) 2022; 17(1): 153-168.

  34. Ho JJ, Adnan AS, Kueh YC, Ambak NJ, Van Rostenberghe H,Jummaat F. Human albumin infusion for treating oedema inpeople with nephrotic syndrome. Cochrane Database SystRev 2019; 7 (7): CD009692. 2019. doi:10.1002/14651858.CD009692.pub2.

  35. Kitsios GD, Mascari P, Ettunsi R, Gray AW. Co-administrationof furosemide with albumin for overcoming diureticresistance in patients with hypoalbuminemia: a metaanalysis.J Crit Care 2014; 29 (2): 253-9. doi: 10.1016/j.jcrc.2013.10.004.

  36. Lee TH, Kuo G, Chang CH, et al. Diuretic effect of co-administrationof furosemide and albumin in comparison tofurosemide therapy alone: An updated systematic reviewand meta-analysis. PLoS One 2021; 16 (12): e0260312.doi:10.1371/journal.pone.0260312.

  37. Mendes RS, Pelosi P, Schultz MJ, Rocco PRM, Silva PL. Fluidsin ARDS: more pros than cons. Intensive Care Med Exp2020; 8 (Suppl 1): 32. doi: 10.1186/s40635-020-00319-x.

  38. Silversides JA, Major E, Ferguson AJ, Mann EE, et al.Conservative fluid management or deresuscitation forpatients with sepsis or acute respiratory distress syndromefollowing the resuscitation phase of critical illness: asystematic review and meta-analysis. Intensive Care Med2017; 43 (2): 155-170. doi:10.1007/s00134-016-4573-3.

  39. National Heart, Lung, and Blood Institute Acute RespiratoryDistress Syndrome (ARDS) Clinical Trials Network,Wiedemann HP, Wheeler AP, et al. Comparison of two fluidmanagement strategies in acute lung injury. N Engl J Med2006; 354 (24): 2564-2575. doi:10.1056/NEJMoa062200.

  40. Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid managementwith a simplified conservative protocol for theacute respiratory distress syndrome. Crit Care Med 2015;43 (2): 288-295. doi:10.1097/CCM.0000000000000715.

  41. Uhlig C, Silva PL, Deckert S, Schmitt J, et al. Albumin versuscrystalloid solutions in patients with the acute respiratorydistress syndrome: a systematic review and meta-analysis.Critical Care 2014; 18: R10. doi: 10.1186/cc13187.

  42. Vlasov H, Juvonen T, Hiippala S, Suojaranta R, et al. Effectand safety of 4% albumin in the treatment of cardiac surgerypatients: study protocol for the randomized, doubleblind,clinical ALBICS (ALBumin In Cardiac Surgery) trial.Trials 2020; 21 (1): 235. doi:10.1186/s13063-020-4160-3.

  43. Moret E, Jacob MW, Ranucci M, Schramko AA. Albumin—beyond fluid replacement in cardiopulmonary bypass surgery:Why, how, and when? Semin Cardiothorac Vasc Anesth2014; 18 (3): 252-259. doi: 10.1177/1089253214535667.

  44. Hanley C, Callum J, Karkouti K, Bartoszko J. Albumin in adultcardiac surgery: a narrative review. L’albumine en chirurgiecardiaque adulte : un compte rendu narratif. Can J Anaesth2021; 68 (8): 1197-1213. doi:10.1007/s12630-021-01991-7.

  45. Wigmore GJ, Anstey JR, St John A, Greaney J, et al. 20%Human albumin solution fluid bolus administration therapyin patients after cardiac surgery (the HAS FLAIR Study).J Cardiothorac Vasc Anesth 2019; 33 (11): 2920-2927.doi:10.1053/j.jvca.2019.03.049.

  46. Gales BJ, Erstad BL. Adverse reactions to human serumalbumin. Ann Pharmacother 1993; 27 (1): 87-94. doi:10.1177/106002809302700119.

  47. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin--serious adverse events reported worldwide in 1998-2000.Br J Anaesth 2003; 91 (5): 625-30. doi: 10.1093/bja/aeg233.




2020     |     www.medigraphic.com